NCT06087835: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) |
|
|
| Recruiting | 3 | 1500 | Europe, Canada, Japan, US, RoW | Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Chronic Kidney Disease With High Proteinuria | 06/27 | 06/27 | | |
ACTRN12618000021279: The anti-anginal effect of Zibotentan in the Coronary Slow Flow Phenomenon (CSFP) |
|
|
| Completed | 2/3 | 50 | | | The University of Adelaide, AstraZeneca Pty Ltd | Coronary Slow Flow Phenomenon | | | | |
